Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TR1801-ADC
- Development stage
- Phase 1
- Lead developer
- Tanabe Research Laboratories
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TR1801-ADC is a next-generation antibody-drug conjugate (ADC) designed for the treatment of solid tumors that overexpress c-Met (Hepatocyte growth factor receptor). It consists of a non-agonizing humanized anti-c-Met monoclonal antibody site-specifically linked to a pyrrolobenzodiazepine (PBD) dimer toxin. The PBD payload acts as a DNA cross-linking agent causing potent cytotoxicity in cancer cells. Preclinical studies have demonstrated high antitumor activity across various solid tumor models—including gastric, colorectal, head and neck cancers—regardless of MET gene copy number or c-Met expression level. The drug was developed by Tanabe Research Laboratories USA in collaboration with Open Innovation Partners and MedImmune/AstraZeneca. Clinical development reached phase I for advanced/metastatic solid tumors but was suspended due to funding withdrawal.
- Other names
- MT-8633MT8633MT 8633TR 1801 ADCTR1801 ADCTR-1801 ADCTR1801-antibody drug conjugateTR-1801-antibody drug conjugateTR 1801-antibody drug conjugate
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)DNA
Beyond the preview
Go deeper on TR1801-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TR1801-ADC.